Cleantech Co. Advances Antimicrobial Wound Care Breakthrough

1. BioLargo Inc. is a billboard sponsor of Streetwise Reports and pays SWR a monthly sponsorship fee between US$3,000 and US$6,000.
2. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of BioLargo Inc.
3. Steve Sobek wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
4. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company. 
5. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

Cleantech innovation company BioLargo Inc. (BLGO:OTCQX) announced that subsidiary Clyra Medical Technologies has made significant strides in product development, commercialization, and clinical initiatives, moving closer to several imminent market launches and global expansion.

Clyra's ViaCLYR, an advanced solution for wound irrigation and antimicrobial treatment, is on track for a commercial debut in late 2025 or early 2026 through a network of established distributors with both domestic and international reach.

The company is also broadening its partnerships with healthcare professionals to conduct focused evaluations supporting its applications in antimicrobial, wound care, and surgical markets. Under a distribution agreement signed earlier this year, Clyra is entering the Europe-Middle East-Africa (EMEA) region through collaborations with international distributors. Initial product sales in this region are expected to commence in late 2025 or early 2026. Initial sales will be limited to countries recognizing existing FDA clearances, while others will require a CE Mark, which is currently in progress.

"Clyra represents a major technical advancement in infection control and wound care," said Dennis P. Calvert, chief executive officer of BioLargo and chairman of Clyra Medical Technologies. "We believe its products will set a new standard in antimicrobial performance and deliver exceptional value to patients, clinicians, and shareholders as adoption expands globally. Clyra exemplifies BioLargo's mission to develop high-impact technologies that create meaningful value for humanity and our investors."

But ViaCLYR is merely the starting point, the company said.

"The company's underlying antimicrobial chemistry platform is designed for use across multiple markets — including surgical infection prevention, wound care, and clinical disinfection," the company told Streetwise in another version of the release. "Management believes that as these applications mature and expand globally, Clyra could represent an enterprise value exceeding US$1 billion exceeding US$1 billion, consistent with peer companies that have successfully scaled proprietary medical technology platforms worldwide."

Clyra Reaches Several Critical Milestones

Following the signing of another distribution agreement in Q2 2025, Clyra has reached several critical milestones toward the commercial launch of its surgical products. These milestones include the completion of packaging and label design, as well as the finalization of product claims.

The next steps, currently underway, focus on product stability testing, packaging validation, and process validation. Upon completion, the entire package will undergo standard FDA submission and review.

The company said its major distribution partner has been involved at every stage of development in preparation for launch. Together, they anticipate that Clyra's surgical application products will be available at over 6,000 hospitals, 6,300 ambulatory surgery centers, and 2,200 specialty wound care clinics across the United States.

Building on its established platform technology, Clyra is developing new product delivery systems and expanding applications for infection prevention and wound management, diversifying its offerings across various medical markets. Management believes this will expand the total addressable markets for Clyra products as they are commercialized.

Clyra has secured over US$7.5 million in funding over the past 12 months to support capital investments, product launches, manufacturing readiness, and market expansion. The company continues to explore strategic funding opportunities to sustain its growth trajectory and maximize shareholder value.

"We are excited to bring these innovations to market and see our years of development translate into real clinical impact," said Clyra Medical CEO Steve Harrison. "Our expanding team remains focused on delivering world-class antimicrobial solutions that improve patient care and safety."

A subsidiary of BioLargo, Inc., Clyra Medical Technologies said it develops innovative antimicrobial and wound care products designed to advance infection control and improve healing outcomes across multiple medical markets.

BioLargo is made up of subsidiaries that work in different sectors, a "family of companies," which also includes ONM Environmental, BioLargo Engineering, BioLargo Energy Technologies, and the BioLargo Equipment Solutions & Technologies Inc. (BEST for PFAS Solutions) subsidiary.

On 'the Cusp of Commercialization'

According to analyst Richard Ryan of Oak Ridge Financial writing on in an updated research note on September 30, "The Clyra story has evolved over 14 years, with upwards of US$20 million being invested and, what appears to be, the cusp of commercialization [on many fronts]."

Ryan continued, "We believe an independent valuation of Clyra and the company's PFAS technology presents investors with underlying support. Given the proven commercial viability of BLGO's PFAS technology, we have included its valuation . . . As a result, we are reaffirming a Buy."

Ryan also called an appointment to the Clyra medical advisory team, Dr. Thomas Shives, "impressive."

Shives earned his medical degree from the University of Iowa, where he was a member of the Alpha Omega Alpha Honor Medical Society. After completing his residency in orthopedic surgery and a fellowship in musculoskeletal oncology, he became a staff surgeon at the Mayo Clinic in Rochester, Minnesota, in 1979, focusing on the treatment of bone and soft-tissue cancers. Throughout his career, he has performed surgeries on over 7,500 patients and was appointed professor of orthopedic surgery in 2001. Shives has authored more than 100 papers and book chapters and founded Mayo Clinic Radio, which is broadcast on nearly 200 stations nationwide. He retired from the Mayo Clinic in 2019.

How the Tech Works

Based in Tampa, Florida, BioLargo owns a 49% ownership stake in Clyra[per last published report]. which specializes in developing medical products utilizing its patented Clyra technology, which involves a copper-iodine complex, as detailed on the company's website.

While remaining safe on tissue, this combination of compounds triggers an oxidative reaction that effectively combats a broad spectrum of disease-causing organisms, including viruses, fungi, spores, and even multidrug-resistant bacteria like Klebsiella pneumoniae. The reaction has demonstrated results as being effective against biofilms, which are bacterial clusters that attach to surfaces or each other and are embedded in a self-produced matrix. Clyra's technology is safe, effective, and biocompatible, and it can be delivered in various forms, such as liquid, dry solution, hydrogel, or embedded in a pad, the company said.

ViaCLYR is a long-acting wound irrigation and management solution designed for acute and chronic wounds and burns. Clyra's products are suitable for use in wound care centers, hospitals, nursing homes, urgent care clinics, home healthcare agencies, military applications, and by consumers, the company said.

The Catalyst: Sector to Grow 'Substantially'

The global market for anti-biofilm wound dressings is projected to experience a 9.8% compound annual growth rate (CAGR) from 2025 to 2035, reaching a value of US$2.4 billion from US$943.5 million, according to Future Market Insights. The rising prevalence of surgical site infections, diabetic ulcers, and chronic wounds is a primary driver of this growth. Biofilms, which contribute to antibiotic resistance and delayed healing, are another factor.

The market in the U.S. is also expected to expand significantly, with a projected 9.3% CAGR during the forecast period, driven by chronic wounds, an aging population, demand for advanced care, technological advancements, and government initiatives, the research firm said.

According to Fact.MR, BioLargo noted, a global provider of data-driven market intelligence, "The global wound irrigation solution market is evaluated at a size of US$732 million in 2024 and has been forecasted to expand at a CAGR of 3.4% to reach US$1.02 billion by the end of 2034." The increasing prevalence of chronic diseases such as diabetes and vascular conditions is driving demand for wound care solutions. Hospitals and clinics are increasingly adopting wound irrigation protocols to prevent surgical site infections.

Ownership and Share Structure

About 13.8% of BioLargo is owned by insiders and management, according to Refinitiv. They include Chief Science Officer Kenneth Code with 8.19%, CEO Calvert with 3.25%, and Director Jack Strommen with 1.58%.

About 0.04% is held by the institution First American Trust, Refinitiv said.

The rest, about 85%, is retail.

Its market cap is US$49.41 million, with about 308.99 million shares outstanding and about 266.36 million free-floating. It trades in a 52-week range of US$0.32 and US$0.14.